The prognostic value of CDKN2A/2B gene inactivation for progression of the disease and response to treatment is highly debatable, due to the small number of patients and the heterogeneous nature of T-ALL. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.